Mental Health · Psychiatry · Neuroscience · June 2026
A comprehensive, medically reviewed reference on escitalopram (Lexapro) — covering its pharmacology, FDA-approved indications for depression and generalized anxiety disorder, how it compares to other SSRIs and SNRIs, critical safety information, and legal access for patients in the United States and internationally.
| Generic Name | Escitalopram oxalate |
| Brand Name | Lexapro |
| Related Agent | Citalopram (Celexa) — the racemic parent compound |
| Drug Class | Selective serotonin reuptake inhibitor (SSRI) |
| FDA Approvals | 2002 (major depressive disorder) · 2003 (generalized anxiety disorder) |
| DEA Schedule | Not a controlled substance |
| Available Doses | 5 mg · 10 mg · 20 mg tablets · 1 mg/mL oral solution |
| Standard Adult Dose | 10 mg once daily, may be increased to 20 mg after at least 1 week |
| Onset of Noticeable Effect | 1–2 weeks for early symptom change; full effect typically 4–8 weeks |
| Half-Life | ~27–32 hours — supports once-daily dosing |
| Food Interaction | None significant — can be taken with or without food |
| Alcohol Interaction | Caution advised — may increase sedation and impair judgment; does not reliably worsen depression but is generally discouraged |
| Boxed Warning | Increased suicidal thinking and behavior in patients under 25, particularly early in treatment |
| Generic Available | Yes — widely available in USA since 2012 |
Escitalopram is the brand name Lexapro's active ingredient — a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration in 2002 for the treatment of major depressive disorder (MDD) in adults and adolescents, and in 2003 for generalized anxiety disorder (GAD) in adults. It is one of the most widely prescribed antidepressants in the United States, valued for its relatively clean side effect profile, straightforward once-daily dosing, and dual approval covering both depression and anxiety.
Escitalopram is the single S-enantiomer of citalopram (Celexa), an earlier SSRI marketed as a racemic mixture of both S- and R-enantiomers. Isolating the S-enantiomer — which carries essentially all of citalopram's serotonin reuptake inhibiting activity — allows escitalopram to achieve comparable or superior antidepressant effect at a lower milligram dose, with a somewhat more favorable tolerability profile in comparative trials.
Generic escitalopram entered the U.S. market in 2012, substantially reducing treatment costs for a medication that had, until that point, only been available as the branded Lexapro product. Major depressive disorder affects an estimated 8% of U.S. adults in a given year, and generalized anxiety disorder affects approximately 3% of U.S. adults annually, with substantial overlap between the two conditions. Escitalopram remains one of the standard first-line pharmacological options for both.
Escitalopram works by selectively inhibiting the reuptake of serotonin (5-hydroxytryptamine, or 5-HT) at the presynaptic neuron, increasing the amount of serotonin available in the synaptic cleft to bind postsynaptic receptors. Serotonin is a neurotransmitter implicated in the regulation of mood, anxiety, sleep, appetite, and a range of other physiological and psychological processes. The precise chain of events linking increased synaptic serotonin to improved mood and reduced anxiety is not fully understood, but is believed to involve downstream adaptive changes in receptor sensitivity and neural signaling that develop gradually over several weeks of continued treatment — which is why SSRIs do not produce an immediate therapeutic effect the way a sedative or stimulant would.
Escitalopram is highly selective for the serotonin transporter relative to other neurotransmitter transporters, including those for norepinephrine and dopamine, which distinguishes it from SNRIs (serotonin-norepinephrine reuptake inhibitors) such as venlafaxine and duloxetine. This selectivity is thought to contribute to escitalopram's comparatively mild side effect profile relative to older antidepressant classes such as tricyclics and MAOIs, which act on a broader range of neurotransmitter systems.
After oral administration, escitalopram is well absorbed regardless of food intake, with peak plasma concentrations reached within approximately 5 hours. Its half-life of approximately 27 to 32 hours supports stable once-daily dosing and a relatively gradual decline in plasma levels if a dose is missed or treatment is discontinued, though abrupt discontinuation after sustained use can still produce a recognized discontinuation syndrome, described further in the warnings section below.
Escitalopram and citalopram are closely related molecules, and the relationship between them mirrors that of armodafinil and modafinil in another therapeutic class: escitalopram isolates the pharmacologically active S-enantiomer from citalopram's racemic mixture. Because the R-enantiomer contributes little to serotonin reuptake inhibition and may even mildly counteract the S-enantiomer's effect, escitalopram achieves a comparable or greater antidepressant and anxiolytic effect at roughly half the milligram dose of citalopram.
Comparative trials and meta-analyses have generally found escitalopram to be at least as effective as citalopram, with several analyses suggesting modestly better tolerability and, in some comparative reviews, a modest efficacy edge. Citalopram also carries an FDA warning regarding dose-dependent QT interval prolongation at higher doses, capping its maximum recommended dose at 40 mg daily (20 mg in certain higher-risk patients) — a constraint escitalopram does not carry to the same degree, though cardiac monitoring considerations still apply in higher-risk patients on any SSRI.
| Feature | Escitalopram (Lexapro) | Sertraline (Zoloft) | Fluoxetine (Prozac) | Venlafaxine (Effexor XR) |
|---|---|---|---|---|
| Drug Class | SSRI | SSRI | SSRI | SNRI |
| FDA Approval | 2002 | 1991 | 1987 | 1993 |
| Standard Dose | 10–20 mg once daily | 50–200 mg once daily | 20–60 mg once daily | 75–225 mg once daily (extended-release) |
| Half-Life | ~27–32 hours | ~26 hours | ~4–6 days (active metabolite) | ~5 hours (~11 hours active metabolite) |
| Approved Indications | MDD, GAD | MDD, OCD, panic disorder, PTSD, social anxiety, PMDD | MDD, OCD, panic disorder, bulimia | MDD, GAD, panic disorder, social anxiety |
| Discontinuation Symptoms | Moderate risk | Moderate risk | Lower risk (long half-life self-tapers) | Higher risk |
| Sexual Side Effects | Common | Common | Common | Common |
| Generic Available | Yes (since 2012) | Yes (since 2006) | Yes (since 2001) | Yes |
Escitalopram is often favored as a first-line choice for patients presenting primarily with depression, generalized anxiety, or both, given its dual FDA approval and comparatively mild side effect profile. Sertraline carries the broadest range of FDA-approved anxiety-related indications and is frequently preferred when panic disorder, PTSD, or OCD symptoms are also present. Fluoxetine's very long half-life makes it distinctive for patients at higher risk of discontinuation symptoms, while venlafaxine, acting on both serotonin and norepinephrine, is often considered when an SSRI alone has not produced an adequate response. The choice between these agents is individualized and guided by symptom profile, prior treatment history, and tolerability.
Major depressive disorder is characterized by persistent low mood, loss of interest or pleasure in previously enjoyed activities, and a range of associated symptoms including changes in sleep, appetite, energy, concentration, and, in more severe cases, thoughts of self-harm, present for at least two weeks and representing a change from prior functioning. Escitalopram is FDA-approved for the treatment of MDD in adults and in adolescents aged 12 to 17, with clinical trials demonstrating significant improvement in standardized depression rating scales compared to placebo over 8-week treatment periods.
Generalized anxiety disorder is characterized by excessive, difficult-to-control worry about a range of everyday concerns, occurring more days than not for at least six months, accompanied by physical symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance. Escitalopram is FDA-approved for the treatment of GAD in adults, with clinical trials demonstrating significant reductions in standardized anxiety rating scales compared to placebo. Many patients with GAD also have co-occurring depressive symptoms, and escitalopram's dual indication allows a single medication to address both presentations.
Escitalopram is available in 5 mg, 10 mg, and 20 mg tablets, as well as a 1 mg/mL oral solution. Dosing is typically initiated at a lower dose and titrated upward based on response and tolerability, reflecting the gradual onset of therapeutic benefit characteristic of SSRIs.
| Adults — MDD or GAD | 10 mg once daily to start. May be increased to 20 mg once daily after a minimum of 1 week if needed and tolerated. Maximum recommended dose: 20 mg per day. |
| Adolescents (12–17) — MDD | 10 mg once daily to start. May be increased to 20 mg once daily after at least 3 weeks if needed and tolerated. |
| Elderly Patients (65+) | 10 mg once daily is generally the recommended target dose, reflecting increased sensitivity and a flatter dose-response relationship observed in this population. |
| Hepatic Impairment | 10 mg once daily is the recommended dose; dose increase to 20 mg is generally not recommended given reduced clearance. |
| CYP2C19 Poor Metabolizers | 10 mg once daily is recommended as the maximum dose, given the risk of higher plasma concentrations from reduced enzymatic clearance. |
| Patients on CYP2C19 Inhibitors (e.g., omeprazole) | Consider a maximum dose of 10 mg per day given the potential for increased escitalopram plasma levels. |
SSRIs, including escitalopram, do not produce an immediate therapeutic effect. Meaningful improvement in mood or anxiety symptoms typically requires 1 to 2 weeks before any noticeable change and 4 to 8 weeks for a fuller assessment of response. Dose increases should not be made more frequently than every 1 to 3 weeks, and patients are encouraged to continue treatment through the initial weeks even if early side effects are more noticeable than therapeutic benefit, discussing any concerns with their prescriber rather than stopping independently.
Escitalopram should be taken once daily, at approximately the same time each day, with or without food. Consistency of timing supports stable plasma concentrations, though its relatively long half-life makes escitalopram somewhat more forgiving of minor timing variation than shorter-acting medications.
If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose, in which case the missed dose should be skipped rather than doubled. Tablets may be taken whole or, for the scored 10 mg and 20 mg tablets, split if a prescriber has directed a specific partial dose.
Escitalopram should be continued for the full duration recommended by the prescriber, even after symptoms improve, since stopping too early is associated with a higher likelihood of relapse. Any decision to stop or adjust the dose — including after symptoms have improved — should be made together with the prescribing physician, generally with a gradual taper rather than abrupt discontinuation.
Escitalopram's side effect profile reflects its serotonergic mechanism of action. Most side effects are mild to moderate, are most prominent in the first 1 to 2 weeks of treatment or after a dose increase, and tend to diminish as the body adjusts.
Nausea is the most commonly reported adverse effect, typically most noticeable in the first days of treatment and improving thereafter. Headache, insomnia or, conversely, drowsiness, and mild dizziness are also frequently reported, and the pattern can vary considerably between individuals.
Sexual side effects, including reduced libido, delayed orgasm, and erectile difficulty in men, are common with escitalopram as with other SSRIs and may persist for the duration of treatment in some patients; these effects should be discussed with a prescriber, as dose adjustment or an alternative medication may help. Increased sweating, dry mouth, and mild gastrointestinal changes are also reported. Fatigue and a sense of emotional blunting or reduced emotional range are described by some patients on longer-term treatment and are worth raising with a prescriber if bothersome.
Escitalopram, like all antidepressants, carries an FDA boxed warning regarding an increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, particularly during the first few months of treatment and following any dose change. This risk must be weighed against the well-established risks of untreated depression itself. Patients in this age group, and their families or caregivers, should be counseled to watch closely for any worsening depression, new or worsening anxiety, agitation, irritability, or unusual changes in behavior, and to contact a physician immediately if these occur. This warning does not indicate that escitalopram causes suicide in most patients; rather, it reflects a statistically observed increase in risk in this specific population that requires close monitoring, especially early in treatment.
Serotonin syndrome is a potentially life-threatening condition resulting from excess serotonergic activity, most often occurring when escitalopram is combined with another serotonergic medication. Symptoms include agitation, hallucinations, rapid heart rate, elevated body temperature, muscle rigidity or twitching, loss of coordination, and gastrointestinal symptoms such as nausea and diarrhea. Onset is typically rapid, often within hours of starting or increasing an interacting medication. Any suspected serotonin syndrome requires immediate medical attention.
Abrupt discontinuation of escitalopram, particularly after several weeks or more of treatment, can produce a discontinuation syndrome involving dizziness, sensory disturbances often described as "brain zaps," irritability, anxiety, headache, and flu-like symptoms. This is distinct from dependence or addiction but can be uncomfortable enough to affect daily functioning. A gradual, physician-guided taper is generally recommended when discontinuing escitalopram after extended use.
SSRIs, including escitalopram, can impair platelet aggregation, modestly increasing the risk of abnormal bleeding, particularly when combined with NSAIDs, aspirin, or anticoagulant medications. Patients should disclose any bleeding disorders and all concurrent medications to their prescriber.
Rare cases of low sodium levels (hyponatremia), sometimes associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), have been reported with SSRIs, more frequently in elderly patients. Symptoms include headache, confusion, weakness, and in severe cases, seizures; any such symptoms during treatment warrant prompt medical evaluation.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| MAOIs | Severe additive serotonergic activity | Serious risk of serotonin syndrome, potentially fatal | Absolute contraindication. Do not use within 14 days of an MAOI in either direction. |
| Other serotonergic medications (triptans, tramadol, other antidepressants, St. John's Wort) | Additive serotonergic activity | Increased risk of serotonin syndrome | Use with caution and physician awareness; monitor for early signs of serotonin syndrome. |
| NSAIDs, aspirin, anticoagulants | Combined effect on platelet function and clotting | Increased risk of abnormal bleeding, including gastrointestinal bleeding | Disclose use of these medications; monitor for signs of unusual bruising or bleeding. |
| CYP2C19 inhibitors (e.g., omeprazole) | Reduced escitalopram metabolism | Elevated escitalopram plasma concentrations | Consider a maximum escitalopram dose of 10 mg per day. |
| Other CNS depressants and alcohol | Additive sedative effect | Increased drowsiness and impaired coordination | Use caution; alcohol is generally discouraged during antidepressant treatment. |
| QT-prolonging medications | Additive effect on cardiac repolarization | Increased risk of cardiac arrhythmia | Disclose all medications to the prescriber; caution advised in patients with cardiac risk factors. |
Agitation, confusion, rapid heart rate, high fever, muscle rigidity or twitching, and loss of coordination occurring after starting escitalopram or adding a new serotonergic medication represent a medical emergency. Seek immediate medical attention and inform providers of all medications and supplements being taken.
Concurrent or recent MAOI use: Absolute contraindication, including within 14 days of stopping an MAOI.
Concurrent use of pimozide: Contraindicated due to a significant risk of QT prolongation and cardiac arrhythmia.
Known hypersensitivity: Contraindicated in patients with a prior hypersensitivity reaction to escitalopram or citalopram.
History of mania or bipolar disorder: Antidepressants, including escitalopram, may trigger a manic episode in patients with underlying bipolar disorder; careful diagnostic evaluation is recommended before starting treatment for depression or anxiety.
Pregnancy and breastfeeding: Use during pregnancy requires an individualized discussion of risks and benefits with a physician, weighing the risks of untreated depression or anxiety against potential medication exposure; escitalopram is present in breast milk and use during breastfeeding should also be discussed with a physician.
Bleeding disorders: Caution required given escitalopram's effect on platelet function, particularly in combination with other medications affecting bleeding risk.
Seizure disorders: SSRIs can lower seizure threshold; caution and monitoring are advised in patients with a history of seizures.
Pediatric patients under 12: Not established as safe or effective for MDD in children under 12, and not FDA-approved for GAD in patients under 18.
Give the medication time to work. Escitalopram's full therapeutic benefit typically takes 4 to 8 weeks to become apparent. Early side effects often precede the therapeutic benefit, and stopping treatment prematurely is one of the most common reasons patients do not experience the medication's full potential effect.
Never stop abruptly after sustained use. Discontinuation syndrome can be uncomfortable and is avoidable in most cases with a gradual, physician-guided taper. Any plan to stop or change the dose should be discussed with the prescriber first.
Disclose every other medication and supplement you take, particularly other antidepressants, migraine medications (triptans), tramadol, St. John's Wort, and any blood-thinning medications, given the serotonin syndrome and bleeding risk interactions associated with escitalopram.
Monitor mood and behavior closely in the first weeks, particularly in patients under 25, and involve a trusted family member or friend in watching for any worsening symptoms, agitation, or unusual behavioral changes, especially after starting treatment or after a dose change.
Limit or avoid alcohol during treatment, as it can compound sedation and may interfere with the mood benefits escitalopram is intended to provide.
Store at room temperature (20–25°C / 68–77°F), away from moisture, heat, and light, and out of reach of children.
In the United States, escitalopram is a prescription medication, not a controlled substance, available from any licensed pharmacy following a physician or qualified prescriber consultation. Generic escitalopram, available since 2012, has substantially reduced the cost of treatment relative to the original branded Lexapro, and generic formulations are bioequivalent to the branded product.
Telehealth consultations for depression and anxiety have expanded considerably, allowing many patients to complete an initial evaluation, begin treatment, and access ongoing follow-up care without an in-person visit, which has meaningfully improved access to mental health treatment for many patients, particularly in areas with limited access to psychiatric care.
Internationally, escitalopram is a prescription medication in all major healthcare markets. The same standard for legitimate pharmacy sourcing applies universally: a mandatory prescription requirement, a verifiable pharmacy license, transparent pricing, and accountable dispensing records. Sourcing escitalopram or any prescription antidepressant from unregulated online vendors carries meaningful risk, including counterfeit or substandard formulations with unpredictable strength.
My Online Med Shop provides genuine, verified escitalopram (Lexapro) and its generic equivalent sourced exclusively from verified pharmaceutical manufacturers, dispensed strictly against a valid prescription, with secure encrypted checkout, discreet packaging, and 24/7 customer support available for every order.
Some patients notice subtle changes, such as improved sleep or reduced physical anxiety symptoms, within the first 1 to 2 weeks, but the fuller antidepressant and anxiolytic effect typically takes 4 to 8 weeks of consistent daily use to become apparent. It is important to continue taking the medication as prescribed during this period, even if early side effects are more noticeable than benefits, and to discuss any concerns with a prescriber rather than stopping independently.
Citalopram is a racemic mixture of two mirror-image molecules, while escitalopram contains only the S-enantiomer, which carries essentially all of citalopram's therapeutic activity. This allows escitalopram to achieve a comparable or greater effect at roughly half the milligram dose, and several comparative studies suggest modestly better tolerability with escitalopram, though both remain effective, widely used SSRIs.
Escitalopram is not a controlled substance and does not produce the euphoria or compulsive-use patterns associated with substances of misuse. However, the body does adapt to its presence over time, and stopping abruptly after sustained use can cause a discontinuation syndrome. This reflects a physiological adjustment rather than addiction, and it is managed by tapering the dose gradually under a physician's guidance.
Weight change with escitalopram is variable; some patients experience modest weight gain with long-term use, while others notice little change or even mild weight loss, particularly early in treatment when appetite or nausea may be affected. Weight change tends to be less pronounced with escitalopram than with some other antidepressants, but individual response varies, and any significant change should be discussed with a prescriber.
Most patients describe escitalopram as reducing excessive sadness or anxiety without fundamentally changing who they are, but a subset of patients report a sense of emotional blunting or a narrower emotional range, particularly with longer-term use. This is a recognized effect worth raising with a prescriber, since a dose adjustment or alternative medication may improve this experience for some patients.
Alcohol is generally discouraged during SSRI treatment. While an occasional drink does not represent a dangerous interaction for most patients, alcohol can worsen sedation, interfere with sleep, and may counteract some of the mood benefits escitalopram is intended to provide. Patients with a history of alcohol use concerns should discuss this specifically with their prescriber.
Abrupt discontinuation, particularly after several weeks or more of treatment, can cause a discontinuation syndrome involving dizziness, sensory disturbances sometimes described as "brain zaps," irritability, anxiety, and flu-like symptoms. These symptoms are uncomfortable but generally resolve with a gradual, physician-supervised taper, which is the recommended approach whenever escitalopram treatment is being discontinued after sustained use.
Yes, and for many patients with moderate to severe depression or anxiety, the combination of medication and psychotherapy, such as cognitive behavioral therapy, produces better outcomes than either approach alone. Escitalopram is often used as one part of a broader treatment plan rather than as a standalone solution, and discussing therapy options with a prescriber or mental health provider is a reasonable step for most patients starting treatment.
Escitalopram (Lexapro) remains one of the most widely prescribed and best-studied SSRIs available, valued for its dual FDA approval for major depressive disorder and generalized anxiety disorder, its comparatively mild side effect profile, and its straightforward once-daily dosing. As the isolated active enantiomer of citalopram, it offers a refined pharmacological profile that has made it a common first-line choice among prescribers treating depression, anxiety, or both.
The availability of generic escitalopram since 2012 has made this treatment accessible to the large number of patients managing depression and anxiety in the United States and worldwide. As with all antidepressants, escitalopram requires patience during the initial weeks of treatment, careful monitoring for mood or behavioral changes, and a gradual, physician-guided approach to any dose change or discontinuation.
Within the parameters of a valid prescription, appropriate diagnostic evaluation, and verified pharmaceutical sourcing, escitalopram has a well-established, extensively documented record as an effective and generally well-tolerated treatment for depression and anxiety, most effective when used as part of a comprehensive approach to mental health that may also include psychotherapy and lifestyle support.
Buy Escitalopram Online USA: Uses, Dosage & Safety Guide 2026
Buy Armodafinil Online USA: Uses, Dosage & Safety Guide 2026
Buy Ambien Online USA: Uses, Dosage & Safety Guide 2026
Buy Cialis Online USA: Uses, Dosage & Safety Guide 2026